NCT04608422

Brief Summary

This study aims to evaluate the effects of electrical stimulation on renal function and physical capacity in patients with chronic kidney disease (CKD). This is a randomized controlled trial with patients from the HD outpatient of Santa Clara hospital at Irmandade Santa Casa de Misericórdia de Porto Alegre (ISCMPA), who will be allocated to a control group (it will be evaluated and reassessed) or intervention group (it will receive electrical stimulation). Interventions will occur during the HD session, twice a week, for eight weeks, totaling 16 sessions. The groups will be evaluated prior to physiotherapy intervention and at the end. The following outcomes will be measured: renal function, functional capacity, muscle strength of lower limbs and quality of life.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2020

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 23, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 29, 2020

Completed
3 days until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2021

Completed
Last Updated

November 2, 2020

Status Verified

October 1, 2020

Enrollment Period

4 months

First QC Date

October 23, 2020

Last Update Submit

October 29, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in soluble α-Klotho protein expression.

    It will be assessed by the analysis of the plasma content by immunoassay assay (ELISA).

    Baseline, after 4 weeks and after 8 weeks.

  • Change in serum creatinine.

    It will be assessed by the analysis of the plasma content by spectrophotometry.

    Baseline, after 4 weeks and after 8 weeks.

Secondary Outcomes (4)

  • Functional capacity.

    Baseline and after 8 weeks.

  • Muscle strength of lower limbs.

    Baseline and after 8 weeks.

  • Muscle strength of quadriceps.

    Evaluated: baseline and after 8 weeks.

  • Quality of life evaluation.

    Baseline and after 8 weeks.

Study Arms (2)

Electrical stimulation

EXPERIMENTAL

The patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.

Other: Electrical stimulation

Control

NO INTERVENTION

The patients only will be evaluated and reassessed.

Interventions

A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).

Electrical stimulation

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with CKF on HD for a period ≥ 3 months;
  • Kt/V ≥ 1.2 or URR ≥ 65%
  • Age between 18 and 80 years old;
  • Functional capacity ≥ 300 meters in the 6MWT.

You may not qualify if:

  • Cognitive dysfunction that prevents the performance of evaluations, as well as an inability to understand and sign the informed consent form;
  • Intolerance to the electrostimulator and/or alteration of skin sensitivity;
  • Patients with sequelae of stroke;
  • Recent acute myocardial infarction (two months);
  • Uncontrolled hypertension (SBP\> 230 mmHg and DBP\> 120 mmHg);
  • Grade IV heart failure according to the New York Heart Association or decompensated;
  • Unstable angina;
  • Peripheral vascular changes in the lower limbs such as deep vein thrombosis;
  • Disabling osteoarticular or musculoskeletal disease;
  • Uncontrolled diabetes (blood glucose\> 300mg/dL);
  • Feverish state and/or active infectious disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Electric Stimulation

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Physical StimulationInvestigative Techniques

Study Officials

  • Rodrigo DM Plentz, PhD

    Federal University of Health Sciences of Porto Alegre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rodrigo DM Plentz, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 23, 2020

First Posted

October 29, 2020

Study Start

November 1, 2020

Primary Completion

February 28, 2021

Study Completion

April 30, 2021

Last Updated

November 2, 2020

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will not share